Urea Cycle Disorders Clinical Trial
— HEP001Official title:
A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Paediatric Patients.
Verified date | October 2020 |
Source | Promethera Biosciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the safety and to appraise the efficacy of one cycle of Hepastem (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC) infusions in paediatric patients suffering from CN or UCD. The study duration: 12 months starting from the day of treatment: 6 months active surveillance and 6 months observation post-infusion.
Status | Completed |
Enrollment | 20 |
Est. completion date | April 2015 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 17 Years |
Eligibility | GENERAL: 1. Subject shows patency of the portal vein and branches, with normal flow velocity in the main portal vein as confirmed by Doppler ultrasound and accessibility of the portal vein, or respectively, accessibility of the umbilical vein. 2. Subject (if capable of signing) and parents or legal representative have provided a written informed assent/consent. 3. Female subjects of childbearing potential need to have a negative pregnancy test and must agree to use an acceptable method of contraception throughout the study. MAIN INCLUSION CRITERIA Crigler-Najjar Syndrome specific: - Patient presents with Crigler-Najjar syndrome type 1. - Patient presents with Crigler-Najjar syndrome type 2, poorly controlled under phenobarbital treatment, or experiencing serious impairment in quality of life. Diagnosis must be confirmed by genetic mutation analysis if not available. Urea Cycle Disorders specific: - Diagnosis of one of the urea cycle disorders of which the disease is of such severity to warrant liver transplantation or alternatives despite full conservative therapy, - subject experiencing serious impairment in quality of life despite full conservative therapy. MAIN EXCLUSION CRITERIA - The subject is 18 years or older at time of screening. - The subject presents acute liver failure, clinical or radiological evidence of liver fibrosis or cirrhosis, presents or has a history of hepatic or extrahepatic malignancy - The patient has a non-corrected cardiac malformation, has a known medical or family history of coagulopathy, had or has a renal insufficiency treated by dialysis. - The subject requires valproate therapy. - The subject has a thrombosis of the portal vein or persisting impairment of anterograde portal blood flow. - The subject has a porto systemic shunt or fistula assessed by Doppler US. - Patients with disease of such severity that liver transplantation is an absolute indication. |
Country | Name | City | State |
---|---|---|---|
Belgium | Saint Luc University Hospital | Brussels | |
Belgium | Universitair Ziekenhuis (UZ) Antwerpen | Edegem | |
France | CHU Bicêtre | Le Kremlin Bicêtre Cedex | |
France | Hôpital Jeanne de Flandre, CHRU Lille | Lille Cedex | |
France | Hôpital des Enfants, CHU de Toulouse | Toulouse cedex 9 | |
Israel | Rambam Medical Center, Meyer Children's Hospital | Haifa | |
Israel | Hadassah Ein-Kerem Medical Center | Jerusalem | |
Israel | Schneider Children's Medical Center of israel | Petach Tikva | |
Italy | Ospedale Pediatrico Bambino Gesu di Roma | Roma | |
United Kingdom | Birmingham Children's Hospital | Birmingham | |
United Kingdom | Great Ormond Street Hospital London | London |
Lead Sponsor | Collaborator |
---|---|
Promethera Biosciences |
Belgium, France, Israel, Italy, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | To characterize the engraftment of HepaStem | By liver biopsy, enzymatic activity (quantitative) on the biopsies or, donor sequences by RT PCR or in situ hybridisation (FISH) or immunohistochemistry. | at 6 month, and optional at 12 month. | |
Primary | Safety of HepaStem in paediatric patients suffering from CN or UCD | Evaluation of the clinical status, portal-vein hemodynamics, morphology of the liver, de novo detection of circulating anti-HLA antibodies, and/or other immune related markers as well as Serious Adverse Events (SAEs) and clinically significant Adverse Events (AEs) related to infusion. | 6 months | |
Secondary | Long-term safety profile of HepaStem in both indications | Assessment of reactogenicity and safety of the treatment during 6 to 12 months post infusion (long-term safety) is evaluated. | From 6 to 12 months post-administration | |
Secondary | Preliminary efficacy of HepaStem in both indications (CN and UCD) and for different weight cohorts | UCD: 13C tracer test to measure ureagenesis, ammonium values, amino acids in plasma, neuropsychological assessment and quality of life indicators: (1) report on actual supportive treatment and any adjustment of diet (protein restriction (low protein diet) and amino acids supplements). (2) report on cognitive skills, behaviour, and health related quality of life effect).
CN: measure of the blood unconjugated bilirubin and serum total bilirubin levels and quality of life indicators: (1) adjustment of duration of phototherapy, (2) report on cognitive skills, behaviour, and (3) health related quality of life effect. |
0-6 months, 6-12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02252770 -
Nitric Oxide Supplementation in Argininosuccinic Aciduria
|
N/A | |
Completed |
NCT01002469 -
Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment
|
N/A | |
Completed |
NCT00986895 -
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
|
Phase 1 | |
Completed |
NCT01257737 -
To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)
|
Phase 4 | |
Recruiting |
NCT05671666 -
Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients
|
N/A | |
Completed |
NCT02489292 -
Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)
|
Phase 2 | |
Completed |
NCT02311283 -
Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment
|
N/A | |
Completed |
NCT00992459 -
Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders
|
Phase 3 | |
Completed |
NCT00551200 -
Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT00947297 -
Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
|
Phase 3 | |
Completed |
NCT02740153 -
PCORI Urea Cycle Disorder Study
|
||
Completed |
NCT02051049 -
Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
|
||
Completed |
NCT00947544 -
Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT01347073 -
Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
|
Phase 3 | |
Completed |
NCT00718627 -
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT03797131 -
Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Disorders
|
N/A | |
Completed |
NCT01549015 -
Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function
|
N/A | |
Terminated |
NCT01541722 -
Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders
|
N/A | |
Completed |
NCT00345605 -
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
|
Phase 2 | |
Recruiting |
NCT00237315 -
Longitudinal Study of Urea Cycle Disorders
|